Healthcare Industry News: colorectal cancer
News Release - December 11, 2012
IsoRay's Cesium-131 Seeds Proves Successful for Brain Cancer Treatment as Presented by Weill Cornell and Barrow Neurological to The Society Of Neuro-OncologySutured Seeds and Seed Sutured Mesh Deliver Impressive Early Results for Both Metastatic Brain Cancer and Meningioma Tumors
RICHLAND, WA--(Healthcare Sales & Marketing Network) - IsoRay Inc. ( NYSE MKT : ISR ), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the presentation of clinical findings at two medical centers of the successful treatment of brain cancers and tumors using IsoRay's patented Cesium-131 (Cs-131) sutured seeds and seed sutured mesh for internal radiation therapy.
Dr. Theodore H. Schwartz and Dr. Gabriella Wernicke, both of Weill Cornell Medical Center, presented their findings during an oral presentation and luncheon lecture for the membership of The Society of Neuro-Oncology (SNO), titled "The study of Neurosurgical Resection and Intra-operative Cesium-131 Radio-isotope Brachytherapy in Patients with newly Diagnosed Brain Metastases," available at http://www.isoray.com/assets/Updated_SNO_Poster.pdf. In the study, which showed Cesium-131's relative effectiveness in treating these tumors compared to other common treatments, the seeded sutures were placed within the resected tumor bed at the time of surgery to provide immediate radiation therapy to it and to a margin depth of 5 mm which is dosed to prevent tumor reoccurrence.
A metastatic, or secondary, brain tumor is one that begins as cancer in another part of the body. Some of the cancer cells may be carried to the brain by the blood or lymphatic fluid, or may spread from adjacent tissue. Metastatic brain tumors are often referred to as lesions or brain metastases. Metastatic brain tumors are the most common brain tumors.
In another presentation for the membership of SNO, Dr. David G. Brachman, Medical Director of Radiation Oncology at St. Joseph's Hospital & Medical Center, Barrow Neurological Institute in Phoenix, Arizona, presented his early experience utilizing Cesium-131 brachytherapy seed sutured mesh implant for treating recurring meningioma tumor. A copy of the presentation is available at http://www.isoray.com/assets/AOS_BrainBrachytherapy_Poster.pdf.
Meningiomas are an assorted set of tumors that develop in membranous layers surrounding the central nervous system. According to the American Brain Tumor Association, meningiomas are the most common primary brain tumor and represent one-third of all brain tumors. These fast growing tumors often reoccur. They cause pressure on the brain, destroying brain cells and causing a variety of health and quality of life problems for the stricken patient. There are both benign and malignant meningioma tumors.
Typically, meningiomas require multiple treatments with external beam radiation following surgery. Treatment in this manner represents great complexity and difficulty. Because tumors are often large and irregular in shape, delivering a precise dose of radiation is problematic.
In Dr. Brachman's study, the sutured mesh was placed over the resected tumor at the time of surgery to provide immediate radiation therapy to the entire tumor bed and margins, which is aimed at preventing tumor reoccurrence. In addition to noting the initial success of this treatment, Dr. Brachman also pointed to Cesium-131's distinctive abilities. "Cesium-131 provides a unique biological advantage regarding the timing of radiation, being utilized at the time of the surgery before tumor cells can repopulate, which helps to maximize the therapeutic benefit of radiation treatment," he explained.
IsoRay CEO Dwight Babcock says these two presentations are just the latest evidence in brain cancer and tumor treatment supporting the continued expansion of use of the Company's pioneering Cesium-131 brachytherapy seeds and liquid isotopes. "We are advancing our domestic and international goal of creating widespread awareness and adoption of Cesium-131 in hopes that these experiences will ultimately make it a standard of care. The exceptional results that have been realized in treating such a wide array of cancers is drawing an increasing number of inquiries from the medical community. We believe Cesium-131's ability to fight cancer and improve the quality of life for the men, women, and children who are battling these devastating cancers distinguishes it from other treatment options."
IsoRay is the exclusive manufacturer of Cesium-131. The pioneering brachytherapy therapy is one of the most significant advances in internal radiation therapy in 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).
In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh, and several new implantable devices.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.
Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including: the advantages of our Cesium-131 seed, the advantages of Cesium-131 in mesh form, whether adoption of Cesium-131 will continue to increase, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether treatment of brain cancer using Cesium-131 will be successful in future cases, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether ongoing patient results with Cesium-131 are favorable and in line with the conclusions of clinical studies and initial patient results, patient results achieved when Cesium-131 is used for the treatment of cancers and malignant diseases beyond prostate, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use Cesium-131 in its various forms, successful completion of future research and development activities, and other risks detailed from time to time in IsoRay's reports filed with the SEC.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.